Trial · NCT01097616
Adverse events437
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 437
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nasopharnygitis | Infections and infestations | Suvorexant LD (TRT Phase) | 18 | 254 | 18 |
| other | nasopharnygitis | Infections and infestations | Suvorexant HD (TRT Phase) | 32 | 383 | 33 |
| other | nasopharnygitis | Infections and infestations | Placebo (TRT Phase) | 34 | 384 | 35 |
| other | nasopharnygitis | Infections and infestations | Suvorexant LD (EXT Phase) | 4 | 100 | 4 |
| other | nasopharnygitis | Infections and infestations | Suvorexant HD (EXT Phase) | 9 | 172 | 10 |
| other | nasopharnygitis | Infections and infestations | Placebo (EXT Phase) | 1 | 151 | 1 |
| other | nasopharnygitis | Infections and infestations | Suvorexant LD (RO, After Suvorexant LD in TRT/EXT) | 1 | 102 | 1 |
| other | nasopharnygitis | Infections and infestations | Placebo (RO, After Suvorexant LD in TRT/EXT) | 0 | 111 | 0 |
| other | nasopharnygitis | Infections and infestations | Suvorexant HD (RO, After Suvorexant HD in TRT/EXT) | 0 | 160 | 0 |
| other | nasopharnygitis | Infections and infestations | Placebo (RO, After Suvorexant HD in TRT/EXT) | 1 | 162 | 1 |
| other | nasopharnygitis | Infections and infestations | Placebo (RO, After Placebo in TRT/EXT) | 1 | 327 | 1 |
| other | nasopharnygitis | Infections and infestations | Suvorexant LD (TRT/EXT Phase): Follow-up | 0 | 254 | 0 |
| other | nasopharnygitis | Infections and infestations | Suvorexant HD (TRT/EXT Phase): Follow-up | 0 | 383 | 0 |
| other | nasopharnygitis | Infections and infestations | Placebo (TRT/EXT Phase): Follow-up | 0 | 384 | 0 |
| other | nasopharnygitis | Infections and infestations | Suvorexant LD (RO, After Suvorexant LD in TRT/EXT): Follow-up | 0 | 102 | 0 |
| other | nasopharnygitis | Infections and infestations | Placebo (RO, After Suvorexant LD in TRT/EXT): Follow-up | 0 | 111 | 0 |
| other | nasopharnygitis | Infections and infestations | Suvorexant HD (RO, After Suvorexant HD in TRT/EXT): Follow-up | 0 | 160 | 0 |
| other | nasopharnygitis | Infections and infestations | Placebo (RO, After Suvorexant HD in TRT/EXT): Follow-up | 1 | 162 | 1 |
| other | nasopharnygitis | Infections and infestations | Placebo (RO, After Placebo in TRT/EXT): Follow-up | 2 | 327 | 2 |
| other | headache | Nervous system disorders | Suvorexant LD (TRT Phase) | 17 | 254 | 19 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01097616/events